Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Accentus Medical is pleased to announce the results of a retrospective review of infection rates associated with orthopaedic limb salvage devices treated with its innovative Agluna® surface technology. Agluna® harnesses the anti-microbial properties of silver ions in preventing device related infection. The technology is supplied by Accentus Medical under licence to Stanmore Implants Worldwide on its custom patient specific limb salvage devices.
The clinical team at Royal Orthopaedic Hospital (ROH), Birmingham, UK, has conducted a study comparing the incidence of early periprosthetic infection in 85 high risk patients who have undergone endoprosthetic reconstruction using Agluna® treated custom endoprostheses, with a control group of 85 patients receiving non-Agluna® treated endoprostheses. In a paper presented to the International Symposium of Limb Salvage, Bologna, 2013, the ROH team reports an overall reduction in postoperative infection rates, from 22.4% in the control group to 11.8% with Agluna® treated implants. The team also concluded a range of other beneficial clinical outcomes:
Professor Tim Briggs, President of the British Orthopaedic Association, commented "Data from the UK National Joint Registry shows that if the infection rate following primary hip replacement in all UK hospitals could be reduced to that of the top ten per cent, the UK government would save £200 million annually and would be able to fund an extra 40,000 primary procedures each year. Agluna® is proving itself to be a cost effective technology in limb salvage surgery. It appears to have the propensity to reduce the incidence and severity of postoperative infection in orthopaedic surgery, and thus deliver substantial clinical and economic benefit to the global orthopaedic industry."
Martin Pickford, Orthopaedic Advisor to Accentus Medical, said "These clinical review findings in the limb salvage sector are impressive. Devices with the Agluna® surface modification rather than a metallic silver coating are showing the clear clinical benefits of optimising surface concentration and release profile of silver ions. I look forward to wider clinical benefits being delivered as the technology is in due course adopted on a broader range of joint reconstructive devices."
Accentus Medical has issued Agluna® licences to Stanmore Implants for limb salvage devices, and to Zimmer for other orthopaedic applications. The company is broadening the clinical application of Agluna® to other sectors such as dental, spinal and cardiac implantable devices.
Philip Agg, Chief Executive, said "These clinical results provide further reinforcement of the commercial potential of Agluna® as the global leading anti-microbial technology for titanium implantable devices. Following the recent management buyout of the company, we are committed to investing in building a long-term successful business supplying the global implantable device industry, founded on our unique intellectual asset base."
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Bones / Orthopedics category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Medical, Accentus. "Agluna® treated devices significantly reduce infection rates." Medical News Today. MediLexicon, Intl., 23 Oct. 2013. Web.
9 Dec. 2013. <http://www.medicalnewstoday.com/releases/267761>
Medical, A. (2013, October 23). "Agluna® treated devices significantly reduce infection rates." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/267761.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.